[Therapy of thrombocytosis in myeloproliferative syndromes using recombinant interferon-alpha-2a].
In a prospective open study 16 consecutive patients with a myeloproliferative syndrome and thrombocytosis were treated with interferon (IFN) alpha-2a. 4 patients had polycythemia vera, 4 essential thrombocythemia, 3 myeloid metaplasia and 5 chronic granulocytic leukemia. Platelet counts decreased in all treated patients within 2 to 12 weeks from a median value of 1010 x 10(9)/l to 350 x 10(9)/l. No primary or secondary resistance was observed. The initial dose of IFN was 9 m U per day. After correction of the thrombocytosis, it was progressively reduced to a minimum dose of 3 m U per week. Despite the good platelet response to IFN, leukocytosis persisted in 3 patients and polycythemia in a further 3. Side effects and poor compliance required discontinuation of therapy in 6 patients. Special attention is focused on the follow-up in 6 patients who have been treated for more than 15 months.
Tichelli
A
A
Abteilung Hämatologie, Departement Innere Medizin, Kantonsspital Basel.
Gratwohl
A
A
Delacrétaz
F
F
Dazzi
H
H
Stebler
C
C
Wernli
M
M
Holdener
E E
EE
Nissen
C
C
Speck
B
B
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000150:complications* / Q000628:therapy; D010865:Pilot Projects; D011446:Prospective Studies; D011994:Recombinant Proteins; D013922:Thrombocytosis / Q000209:etiology / Q000628:therapy*
D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins
Therapie der Thrombozytose bei myeloproliferativen Syndromen mit rekombinantem Interferon-alpha-2a.